coronavirus
cov
belong
subfamili
orthocoronavirina
famili
coronavirida
order
nidoviral
four
genera
within
subfamili
orthocoronavirina
name
alphacoronaviru
betacoronaviru
gammacoronaviru
cov
deltacoronaviru
cov
genom
envelop
positivesens
singlestrand
rna
size
vari
kb
kb
largest
genom
known
rna
virus
genera
known
infect
mammal
whilst
cov
infect
bird
two
recent
outbreak
viral
pneumonia
caus
sever
acut
respiratori
syndrom
sar
middl
east
respiratori
syndrom
mer
outbreak
sar
first
report
china
spread
quickli
worldwid
result
hundr
death
mortal
rate
maris
recent
progress
provid
framework
prevent
treatment
genom
kb
size
encod
larg
nonstructur
polyprotein
proteolyt
cleav
gener
protein
structur
protein
accessori
protein
fig
four
structur
protein
consist
spike
surfac
glycoprotein
membran
protein
envelop
e
protein
nucleocapsid
n
protein
essenti
assembl
infect
spike
surfac
glycoprotein
play
key
role
attach
host
cell
cleav
host
proteas
ntermin
subunit
membranebound
ctermin
region
bind
subunit
host
receptor
destabilis
prefus
trimer
lead
shed
subunit
transit
subunit
highli
stabl
postfus
conform
order
engag
host
receptor
receptorbind
domain
rbd
subunit
undergo
hingelik
conform
movement
transient
hide
expos
determin
receptor
bind
two
state
subunit
regard
conform
conform
former
repres
inaccess
state
receptor
wherea
latter
correspond
access
state
therefor
understand
structur
function
spike
protein
help
develop
monoclon
antibodi
drug
guid
design
develop
vaccin
seventh
member
famili
cov
infect
human
four
human
cov
abl
caus
wide
rang
upper
respiratori
tract
infect
common
cold
wherea
sarscov
merscov
respons
atyp
pneumonia
caus
differ
infect
site
like
relat
presenc
dipeptidyl
peptidas
angiotensinconvert
enzym
lower
respiratori
tract
major
human
receptor
surfac
spike
glycoprotein
merscov
sarscov
respect
genet
sequenc
similar
sarscov
capabl
use
cell
entri
receptor
sarscov
infect
human
howev
differ
key
protein
virus
use
interact
host
cell
spike
bind
human
approxim
higher
affin
sarscov
spike
make
easier
spread
human
human
upon
entri
alveolar
epitheli
cell
replic
rapidli
trigger
strong
immun
respons
result
cytokin
storm
syndrom
pulmonari
tissu
damag
cytokin
storm
syndrom
also
known
hypercytokinaemia
group
disord
characteris
uncontrol
product
proinflammatori
cytokin
import
caus
acut
respiratori
distress
syndrom
ard
multipl
organ
failur
analysi
first
confirm
case
infect
reveal
cytokin
storm
syndrom
occur
patient
sever
patient
ard
among
deterior
within
short
period
time
die
multipl
organ
failur
addit
number
total
tcell
tcell
tcell
decreas
patient
infect
surviv
tcell
function
exhaust
suggest
decreas
immun
function
patient
ard
decreas
immun
function
secondari
infect
worsen
respiratori
failur
sinc
decemb
multipl
case
patient
pneumonia
unknown
caus
success
report
chines
citi
wuhan
share
histori
exposur
huanan
seafood
market
wuhan
diseas
confirm
acut
respiratori
infect
caus
novel
cov
date
number
patient
without
histori
exposur
huanan
seafood
market
significantli
increas
addit
case
without
histori
travel
wuhan
emerg
earli
phenomena
suggest
possibl
humantohuman
transmiss
jid
antag
april
present
nation
health
commiss
peopl
republ
china
record
total
confirm
case
pneumonia
infect
provinc
district
citi
includ
seriou
ill
death
march
suspect
case
record
close
contact
confirm
patient
track
peopl
releas
medic
observ
day
peopl
still
undergo
medic
observ
total
confirm
case
report
macao
special
administr
region
sar
n
hong
kong
sar
n
taiwan
republ
china
n
addit
china
differ
countri
western
pacif
asia
northern
america
eastern
mediterranean
southeast
asia
african
europ
report
confirm
case
diseas
make
total
talli
confirm
case
worldwid
initi
sourc
still
unknown
although
first
case
link
huanan
seafood
market
wuhan
citi
besid
seafood
report
social
media
wild
anim
includ
bird
snake
marmot
bat
sold
huanan
seafood
market
report
environment
sampl
obtain
marketplac
come
back
posit
novel
cov
specif
anim
identifi
recent
sever
studi
suggest
bat
may
potenti
natur
host
whole
genomewid
nucleotid
sequenc
ident
bat
cov
importantli
isol
pangolin
found
isol
pangolin
cov
genom
similar
suggest
pangolin
may
potenti
intermedi
host
howev
whether
transmit
directli
bat
intermedi
host
requir
confirm
learn
role
camel
mer
civet
sar
hunt
sourc
help
determin
zoonot
transmiss
pattern
stem
ongo
outbreak
novel
cov
transmit
human
via
respiratori
droplet
notabl
respiratori
tract
probabl
rout
transmiss
close
contact
also
sourc
transmiss
exampl
transmit
direct
indirect
contact
mucou
membran
eye
mouth
nose
also
possibl
aerosol
transmiss
rel
close
environ
continu
exposur
high
concentr
aerosol
moreov
report
patient
gastrointestin
symptom
includ
diarrhoea
nausea
vomit
recent
studi
show
enter
symptom
pneumonia
associ
invad
enterocyt
suggest
digest
tract
potenti
rout
infect
besid
respiratori
tract
howev
addit
studi
requir
test
possibl
addit
whether
transmiss
occur
via
breast
milk
vertic
mother
infant
determin
popul
gener
suscept
elderli
peopl
underli
diseas
low
immun
function
like
becom
sever
case
addit
pregnant
women
newborn
infect
also
prone
develop
sever
pneumonia
thu
vulner
patient
consid
focu
prevent
manag
infect
mean
incub
period
estim
day
rang
day
indic
long
transmiss
period
estim
latenc
consist
known
human
cov
includ
nonsar
human
cov
mean
day
rang
day
sarscov
mean
day
rang
day
merscov
mean
day
rang
day
moreov
report
asymptomat
patient
incub
period
effect
transmit
differ
sarscov
sarscov
case
infect
superspread
sarscov
case
infect
suscept
person
incub
period
taken
togeth
data
fulli
support
current
period
activ
monitor
recommend
day
basic
reproduct
number
import
threshold
relat
transmiss
viru
usual
express
r
nought
r
r
implicitli
defin
averag
number
secondari
infect
produc
infecti
person
gener
believ
r
number
infect
case
increas
exponenti
caus
epidem
even
pandem
liu
et
al
review
r
found
estim
rang
mean
higher
sarscov
r
onset
diseas
main
manifest
fatigu
fever
dri
cough
myalgia
dyspnoea
less
common
symptom
nasal
congest
headach
runni
nose
sore
throat
vomit
diarrhoea
sever
patient
often
dyspnoea
andor
hypoxemia
week
onset
septic
shock
ard
difficulttocorrect
metabol
acidosi
coagul
dysfunct
develop
rapidli
note
sever
critic
patient
also
present
low
fever
even
obviou
fever
mild
patient
show
low
fever
mild
fatigu
pneumonia
asymptomat
mild
case
also
spread
human
recent
xu
et
al
report
patholog
featur
first
patient
known
die
infect
biopsi
sampl
obtain
lung
tissu
patient
found
patholog
featur
relat
ard
exampl
evid
desquam
pneumocyt
hyalin
membran
format
seen
lung
tissu
indic
ard
moreov
interstiti
mononuclear
inflammatori
infiltr
observ
lung
tissu
multinucl
giant
cell
atyp
enlarg
pneumocyt
characteris
larg
nuclei
promin
nucleoli
amphophil
granular
cytoplasm
observ
intraalveolar
space
suggest
viral
cytopathiclik
chang
patholog
characterist
highli
similar
seen
sarscov
merscov
infect
taken
togeth
understand
patholog
characterist
sever
case
could
help
provid
new
insight
pathogenesi
pneumonia
may
help
physician
formul
time
strategi
treatment
similar
sever
patient
decreas
mortal
ct
often
found
posit
patient
develop
persist
cough
fever
unexplain
fatigu
typic
ct
present
patient
includ
bilater
pulmonari
parenchym
groundglass
opac
pulmonari
consolid
nodul
bilater
diffus
distribut
sometim
round
morpholog
peripher
lung
distribut
earli
cours
diseas
chest
imag
show
multipl
small
patchi
shadow
interstiti
chang
evid
lung
peripheri
sever
case
spread
bronchi
progress
diseas
gradual
spread
whole
lung
infrequ
interlobar
pleural
thicken
pleural
effus
rapid
accur
detect
essenti
control
outbreak
nucleic
acid
detect
major
method
laboratori
diagnosi
revers
transcript
quantit
pcr
rtqpcr
molecular
biolog
diagnosi
technolog
base
nucleic
acid
sequenc
complet
genom
sequenc
avail
genbank
thu
nucleic
acid
detect
rtqpcr
viral
gene
sequenc
nasopharyng
oropharyng
swab
stool
sputum
blood
sampl
howev
collect
specimen
type
healthcar
worker
requir
close
contact
patient
pose
risk
spread
viru
healthcar
worker
moreov
collect
nasopharyng
oropharyng
specimen
may
caus
bleed
especi
patient
thrombocytopenia
importantli
et
al
found
could
effect
detect
saliva
specimen
infect
patient
suggest
saliva
promis
noninvas
specimen
type
diagnosi
monitor
infect
control
patient
besid
rtqpcr
zhang
et
al
describ
protocol
use
crisprbas
sherlock
specif
highsensit
enzymat
report
unlock
techniqu
detect
use
synthet
viru
rna
fragment
author
found
techniqu
abl
consist
detect
target
sequenc
rang
copi
per
microlitr
input
test
read
use
dipstick
h
without
requir
elabor
instrument
compar
rtqpcr
sherlock
techniqu
accur
detect
time
reduc
onehalf
thu
use
sherlock
techniqu
detect
clinic
patient
sampl
expect
suspect
confirm
case
treat
design
hospit
effect
isol
protect
condit
suspect
case
treat
singl
room
isol
confirm
case
treat
ward
moreov
critic
case
need
admit
intens
care
unit
soon
possibl
gener
treatment
strategi
includ
bed
rest
support
treatment
ensur
suffici
energi
intak
maintain
constant
intern
environ
water
electrolyt
intern
environ
factor
monitor
vital
sign
heart
rate
puls
blood
pressur
oxygen
satur
respiratori
rate
etc
ifn
member
famili
type
ifn
play
import
role
host
resist
viral
infect
ifn
suppress
viral
infect
directli
interf
replic
viru
promot
innat
adapt
immun
respons
vitro
experi
show
ifn
effect
inhibit
replic
sarscov
also
report
cynomolgu
monkey
protect
infect
sar
cov
treatment
ifn
moreov
therapeut
benefit
synthet
recombin
ifn
patient
sar
demonstr
pilot
clinic
trial
thu
ifn
consid
candid
drug
therapi
lopinavirritonavir
first
known
proteas
inhibitor
interfer
replic
synthesi
human
immunodefici
viru
hiv
lead
product
immatur
noninfecti
viru
particl
report
ritonavir
lopinavir
bind
endopeptidas
proteas
evalu
molecular
model
suggest
lopinavirritonavir
may
exert
antivir
effect
inhibit
protein
synthesi
addit
sever
line
evid
show
treatment
lopinavirritonavir
alon
combin
antivir
drug
shown
improv
outcom
sever
patient
sar
mer
amelior
ard
given
similar
two
virus
lopinavirritonavir
may
benefici
effect
futur
studi
need
test
possibl
ribavirin
nucleosid
analogu
broad
antivir
activ
prevent
replic
rna
dna
virus
suppress
activ
inosin
monophosph
dehydrogenas
requir
synthesi
guanosin
triphosph
gtp
ribavirin
wide
use
treat
sar
patient
without
concomit
use
steroid
outbreak
sar
hong
kong
thu
ribavirin
could
consid
treatment
option
patient
chloroquin
wide
use
antimalari
autoimmun
diseas
drug
recent
chloroquin
report
potenti
broadspectrum
antivir
drug
wang
et
al
found
chloroquin
effect
suppress
recent
emerg
novel
cov
vitro
chloroquin
cheap
safe
drug
use
year
thu
potenti
clinic
applic
arbidol
antivir
drug
influenza
infect
wide
use
russia
china
arbidol
arbidol
mesyl
shown
potent
inhibitori
effect
reduc
reproduct
sarscov
vitro
lowlevel
evid
includ
retrospect
cohort
studi
case
report
case
seri
reveal
arbidol
alon
combin
antivir
drug
produc
certain
benefit
treatment
pneumonia
current
mani
randomis
clinic
control
trial
carri
studi
efficaci
arbidol
pneumonia
china
nucleosid
analogu
remdesivir
report
inhibit
sarscov
merscov
vivo
recent
jid
antag
april
vitro
studi
show
remdesivir
potent
block
infect
lowmicromolar
concentr
show
high
select
index
addit
first
case
infect
usa
treat
intraven
remdesivir
patient
condit
deterior
although
remdesivir
benefit
treatment
pneumonia
randomis
control
trial
still
requir
determin
efficaci
safeti
taken
togeth
antivir
drug
may
promis
treatment
option
treatment
howev
also
point
worth
note
potenti
interact
antivir
drug
therapeut
drug
consid
ii
advers
reaction
caus
lopinavirritonavir
diarrhoea
nausea
vomit
liver
damag
also
consid
iii
recommend
use
three
antivir
drug
time
use
relat
drug
stop
intoler
side
effect
iv
evalu
efficaci
current
antivir
drug
clinic
applic
need
nk
cell
import
immun
cell
necessari
defenc
microbeinfect
stress
malign
cell
human
nk
cell
lyse
antibodyco
virusinfect
cell
via
process
antibodydepend
cellular
cytotox
adcc
way
nk
cell
specif
almost
virusinfect
cell
sever
studi
shown
nk
cell
exert
antivir
activ
mediat
adcc
sarscov
herp
simplex
viru
type
cytomegaloviru
hiv
umbil
cord
blood
promis
sourc
allogen
nk
cell
recent
sorrento
celular
announc
launch
clinic
collabor
aim
extend
use
allogen
offtheshelf
umbil
cord
bloodderiv
nk
cell
therapi
treatment
newli
emerg
infect
whilst
develop
new
drug
new
vaccin
clinic
trial
old
drug
carri
nk
cell
therapi
enhanc
immun
current
feasibl
strategi
treatment
prevent
pneumonia
well
known
msc
strong
antiinflammatori
immunomodulatori
function
umbil
cord
blood
placenta
good
sourc
msc
numer
studi
shown
treatment
msc
amelior
acutechron
lung
injuri
ard
suppress
infiltr
immun
cell
pulmonari
tissu
proinflammatori
cytokin
secret
addit
msc
contribut
reduc
lung
fibrosi
enhanc
tissu
repair
besid
routin
antivir
treatment
import
treat
cytokin
storm
syndrom
ard
acut
lung
injuri
patient
sever
prevent
progress
diseas
reduc
mortal
thu
msc
may
promis
therapeut
option
antivir
antibodi
igg
iga
igm
ige
igd
found
convalesc
plasma
recov
patient
effect
treat
patient
viral
infect
convalesc
plasma
therapi
wide
use
infecti
diseas
poliomyel
influenza
ebola
addit
passiv
immunis
also
achiev
use
convalesc
plasma
patient
sarscov
infect
report
small
number
sarscovinfect
patient
taiwan
hong
kong
receiv
treatment
convalesc
plasma
earli
cours
diseas
certain
clinic
benefit
includ
reduct
plasma
viral
load
copiesml
undetect
level
h
plasma
transfus
thu
convalesc
plasma
could
theoret
promis
option
treatment
prevent
infect
although
test
clinic
remiss
epidem
may
depend
develop
monoclon
antibodi
previou
studi
identifi
number
effect
monoclon
antibodi
target
sarscov
spike
protein
prevent
viru
enter
host
cell
acid
residu
receptorbind
domain
rbd
spike
protein
key
target
neutralis
monoclon
antibodi
sarscov
neutralis
monoclon
antibodi
found
bind
noncompetit
sarscov
rbd
neutralis
viru
synergist
manner
recent
studi
show
could
combin
effect
rbd
k
nm
moreov
epitop
overlap
bind
site
rbd
thu
could
promis
therapeut
candid
alon
combin
neutralis
monoclon
antibodi
treatment
pneumonia
glycyrrhizin
activ
compon
liquoric
root
use
chines
medicin
could
effect
inhibit
replic
sarsassoci
cov
vitro
furthermor
high
dose
glycyrrhizin
use
clinic
trial
compound
report
clinic
effect
treatment
sar
time
recent
glycyrrhizin
predict
abil
bind
potenti
effect
hesperetin
wellknown
tradit
chines
medicin
natur
predomin
flavonoid
found
citru
fruit
hesperetin
dosedepend
suppress
cleavag
activ
proteas
sarscov
cellfre
cellbas
assay
hesperetin
also
report
potenti
inhibit
therefor
block
infect
baicalin
anoth
tradit
chines
herbal
medicin
flavon
isol
scutellaria
baicalensi
shown
baicalin
antivir
activ
clinic
isol
sarscov
neutralis
test
addit
quercetin
plant
flavon
wide
use
tradit
chines
medicin
botan
medicin
quercetin
report
exert
antivir
effect
inhibit
sarscov
block
entri
sarscov
host
cell
therefor
studi
suggest
chines
medicin
also
play
key
role
prevent
treatment
pneumonia
sarscov
first
appear
rapidli
spread
countri
region
world
experienc
outbreak
merscov
recent
newli
emerg
undoubtedli
warn
confirm
enter
lung
cell
bind
besid
pulmonari
tissu
also
highli
express
tissu
includ
bile
duct
liver
gastrointestin
organ
small
intestin
duodenum
oesophagu
testi
kidney
thu
organ
may
also
damag
current
spread
rapidli
multipl
countri
caus
sever
ill
sustain
humantohuman
transmiss
make
concern
seriou
publichealth
threat
consid
global
threat
health
caus
jid
antag
april
effect
prevent
treatment
pneumonia
urgent
need
howev
develop
drug
pathogen
still
major
problem
human
current
offici
approv
drug
treat
view
epidemiolog
characterist
crucial
interrupt
spread
viru
epidem
prevent
control
method
isol
infect
patient
control
sourc
infect
time
wild
anim
traffick
must
ban
reduc
spread
cov
addit
necessari
make
full
use
current
limit
evid
therapeut
drug
develop
strategi
drug
applic
prevent
control
transmiss
confirm
genom
sequenc
share
high
ident
bat
human
sarscov
number
antivir
drug
treatment
method
sarscov
infect
also
consid
treatment
prevent
pneumonia
warn
three
time
recent
year
cov
highli
vulner
publichealth
intervent
strategi
increas
incid
cov
emerg
livestock
anim
popul
identif
novel
cov
reservoir
speci
support
view
therefor
addit
develop
new
drug
clinic
trial
old
drug
design
develop
vaccin
also
need
lesson
sarscov
merscov
suggest
research
focu
establish
anim
model
recapitul
variou
aspect
human
diseas
determin
vaccin
safeti
efficaci
fund
work
support
natur
scienc
foundat
china
no
